[SF Business Times] Gilead’s $1,000-a-pill hepatitis C drug may make financial sense for prisons

Oct 20, 2014

Pricey new hepatitis C drugs, such as Gilead Sciences Inc.’s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers.

Sovaldi’s $1,000-a-pill price — or $84,000 for a 12-week course of treatments — has been criticized by pharmacy benefits manager Express Scripts (NASDAQ: ESRX) and others for potentially breaking private and public insurance programs. At the same time, leaders of Foster City-based Gilead (NASDAQ: GILD) have argued that Sovaldi actually saves money in the long term by preventing the use of liver cancer drugs and liver transplants.

[button title=”Read More” link=”http://www.bizjournals.com/sanfrancisco/blog/biotech/2014/10/gilead-sovaldi-hepatitis-c-prisons-stanford.html” target=”_blank” size=”” color=”” class=””]